ANI Pharmaceuticals bids $560M for rare-disease drugmaker Egetis
What's the deal? ANI Pharmaceuticals has made a recommended cash offer to acquire Sweden's Egetis TherapeuticsDealroom has a profile for this one. Try Dealroom → for US$1.36 per share, valuing the deal at about $560 million. The offer carries a 27% premium to Egetis' 60-day volume-weighted average price and is unanimously backed by Egetis' board.
Why now? The bid follows a key milestone for Egetis: US approval of its lead drug, EMCITATE, on September 28, 2026 — the first treatment for peripheral thyrotoxicosis associated with MCT8 deficiency, an ultra-rare genetic disorder affecting roughly one in 70,000 males. The drug was approved in Europe in February 2025.
What's the endgame? ANI, based in Princeton, New Jersey, is pushing to make rare-disease products the bulk of its revenue. It estimates EMCITATE could reach over $300 million in peak sales, with orphan drug exclusivity and patent protection running into 2045.
“The proposed transaction reflects the disciplined execution of the strategy we have consistently outlined,” said Nikhil Lalwani, ANI's president and chief executive officer.
What's in the terms? On November 4, Egetis agreed to sell a Rare Pediatric Disease Priority Review Voucher. Adjusted for those proceeds, ANI values the enterprise at about $434 million. The offer is not subject to financing conditions.
What could go wrong? Completion requires acceptances covering more than 90% of Egetis shares, plus regulatory and competition clearances. The sales opportunity is also unproven: Egetis cited the cost and execution risks of building a standalone US launch as part of its rationale for accepting.
The signal: The deal is a bet on a newly approved product in an ultra-rare indication, with durable exclusivity and a defined launch runway. For ANI, buying commercialisation-ready assets rather than building them is becoming the template for its transformation into a rare-disease company.
Read more: pr.lakeoconeebreeze.net
Image credit: NavyMedicine
